Gastric cancer is the second cause of cancer that is related to death and the fourth most common cancer, worldwide. Complete resection of cancer is the only curative treatment for gastric cancer. However, even if complete resection is possible, recurrence is frequently observed in Gastric patients. Therefore, adjuvant treatment modality for resectable gastric cancer is needed to increase the survival of patients. This study wants to describe the role of adjuvant chemotherapy for resectable gastric cancer, with updated data of recent studies.
Introduction
Gastric cancer is the second cause of cancer related death worldwide, with 988,000 new cases and 736,000 deaths per year.(1) Despite decreasing frequency of worldwide, the high incidence of gastric cancer is a still major health concern in Eastern countries such as Korea and Japan. Complete resection of cancer is the only curative treatment for gastric cancer. However, even if complete resection is possible, recurrence is so frequent at later.(2) So adjuvant treatment for resectable gastric cancer is needed to increase the survival of patients. So many phase II or phase III trials were undertaken to detect the role of adjuvant chemotherapy for resectable gastric cancer. However until recently published, well designed phase III studies, (1, 3) there is no consensus about adjuvant chemotherapy for gastric cancer. And the clinical practice of the management for gastric cancer is so diverse according to countries such as the extent of resection of gastric cancer, whether inclusion of radiotherapy or not, and timing of adjuvant chemotherapy. The D2 dissection is traditionally considered as standard treatment in Eastern countries.
However western countries usually prefer to do dissection of lymph nodes with less than D2 dissection due to result of early Dutch trial that showed no benefit of D2 dissection.(3) However, long term follow up Dutch trials showed a reduction of cancer related death with surgery with D2 dissection.(4) Taiwanese study also supported benefit of D2 lymph node dissection for gastric cancer.(5) These studies supported rationale for the D2 dissection of gastric cancer worldwide when D2 surgery is done by experienced surgeons. (6) With recently published, well designed phase III trials for D2 dissection for gastric cancer and large scaled, patient's data driven.
This study wants to describe the role of adjuvant chemotherapy for resectable gastric cancer with updated data of recent studies not the radiotherapy or perioperative chemotherapy.
Meta-Analysis of Adjuvant Chemotherapy
Several groups published the meta-analysis of data of adjuvant chemotherapy for gastric cancer for decades. The recently published meta-analysis studies suggest the benefit of adjuvant chemotherapy for gastric cancer, however they did not demonstrate consensus of chemotherapeutic regimen, schedule, and duration of treatment for adjuvant chemotherapy for gastric cancer.
Previous large scaled phase III Japanese trial with mitomycin C, fluorouracil, and followed oral UFT, a combination of tegafur, a prodrug of 5-fluorouracil (5-FU) and uracil treatment did not show significant difference between two groups.(15) They considered that negative result was from high proportion of T1 patients in their patients, because at these staged patients, the surgery alone yields a very good survival rate and there seemed no need for adjuvant therapy. The authors concluded that patients with T1 staged patients with gastric cancer should be excluded from further adjuvant chemotherapy trial, after that, following trials usually excluded these stage patients.
Adjuvant Chemotherapy for Extended Surgery Using D2 Lymph Node Dissection
The role of adjuvant chemotherapy for resectable gastric cancer was still remained to be answer to question, because so many pre- Rougier and Sakamoto (18) showed that 3 year disease free survival was strongly correlated with 5 year overall survival and disease free survival was shown to be a relevant surrogate of overall survival.
They collected 1,035 patients who were randomly assigned to receive either oxaliplatin/capecitabine combination group (n=520) or surgery (n=515). 3 year disease free survival was higher in the chemotherapy group than in the surgery alone group (HR 0.56, 95% CI 0.44~0.72; P＜0.0001),(1) 3 year disease free survival was 74% (95% CI 67~79) in the chemotherapy group and 59% (95% CI 53~64)
in the surgery only group. In subgroup analysis, they showed the significant benefit through at all disease stage (II, III, and IIIB) that
was not demonstrated at ACTS-GC study and patients with further nodal involvement could be more benefit (N2＞N1＞N0 
Conclusions
Recently published studies supported that adjuvant chemotherapy could be benefit for resectable gastric cancer with extended lymph node dissection. However further clinical trials should be undertaken to make a consensus which regimen is better than others, time duration of adjuvant chemotherapy, and how to apply with multimodal treatment options. Further phase III trials to determine the best regimen and schedule of adjuvant chemotherapy was suggested to use the fluoropyrimidine based regimen as a control group.
